Business · 18/10/2018Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for OCREVUS Patent Extension
Summary
The Food and Drug Administration (FDA) has determined the regulatory review period for the patent extension of OCREVUS, allowing the medication to remain on the market for an additional 15 years.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →